ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite medical treatment, lasting 3 months) do not present obstructive coronary artery disease (ANOCA). Between 60 to 90% is due to coronary vasomotor dysfunction (CVDys) which might be interpreted as vessel spasm or microvascular dysfunction. 

ACC 2022 - Estudio EDIT-CMD

A recent publication from the European Society of Cardiology about ANOCA recommends the use of several drugs such as calcium blockers, beta blockers, ACE inhibitors, statins or nitric acid modulators. 

The study EDIT-CMD looked into the effect of diltiazem in the treatment of coronary vasomotor dysfunction compared vs placebo in patients with ANOCA, through coronary function testing. (CFT).

A randomized study was carried out, double blind, including 85 patients, mean age 58, receiving a CFT, consisting of a diagnostic coronary angiography, a spasm provoking test with acetylcholine and a microvascular function test with adenosine. Primary end point was treatment success defined as normalization of at least one abnormal CVDys parameter at 6 months. 

Read also: ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI.

The primary end point was observed in 21% of patients in the diltiazem group vs. 29% in the placebo group, with non-significant reduction (p=0.46). For both the more positive scenario and the negative, the use of diltiazem did not show important therapeutical success. 47% of patients in the intervention branch progressed from epicardial to microvascular spasm compared against 6% in the placebo group.

Conclusions

This is the first randomized study to look at the effect of CVDys in patients with ANOCA, and it’s concluded that diltiazem does not reduce coronary vasospasm and does not improve microvascular angina or quality of life.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board, SOLACI.org

Original Title: EDIT-CMD: Efficacy of Diltiazem to improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries (ANOCA): Results of the EDIT-CMD randomized clinical trial.

Reference: Jansen, T. P. J., Konst, R. E., de Vos, A., Paradies, V., Teerenstra, S., van den Oord, S. C. H., Dimitriu-Leen, A., Maas, A. H. E. M., Smits, P. C., Damman, P., van Royen, N., & Elias-Smale, S. E. (2022). Efficacy of Diltiazem to improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries (ANOCA): Results of the EDIT-CMD randomized clinical trial. JACC. Cardiovascular Imaging. https://doi.org/10.1016/j.jcmg.2022.03.012.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...